Browse by category

Viking Therapeutics has completed patient enrolment in its Phase 3 VANQUISH-1 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity. The Phase 3 VANQUISH-1 study is a randomised, double-blind, placebo-controlled, multi-centre t

A research team has developed a fluorescent probe that allows scientists to visualise how individual lipid droplets break down inside living cells in real-time. The probe changes its fluorescence properties depending on the chemical composition of each droplet, which allows researchers to observe not only their location within cells, but also their metabolic activity during lipid breakdown. The findings may contribute to the development of new strategies to treat metabolic di

Obesity severity is incrementally associated with a broad range of cardiometabolic and renal disease burden, as discovered by researchers at Pennington Biomedical Research Center. In a presentation by Dr Florina Corpodean titled, ‘Associations of Obesity Severity with Cardiometabolic and Renal Disease Burden in the United States," at ObesityWeek 2025, she explored the relationship through a cross-sectional study of data from the US Behavioral Risk Factor Surveillance System s

Outcomes from the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) has met the primary endpoints and all key secondary endpoints. Innovent Biologics plans to submit the new drug application (NDA) of mazdutide 9 mg for weight management to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) in the near term. GLORY-2 is

Nearly two-thirds of Americans (63%) know that obesity is a chronic disease rather than a personal failure and more than 8 in 10 believe that insurance should cover its treatment, whether it be medications or surgeries, according to a new nationwide survey conducted by The Harris Poll on behalf of the American Gastroenterological Association (AGA). Adult Obesity Rate by State, 2024 (State of Obesity 2025: Better Policies for a Healthier America’, Trust for America’s Health) "

Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have looked far and wide to give you an overview of papers including long-term outcomes of RYGB vs SG, gallstone formation post RYGB and SG, combination of OAGB with modified fundoplication improves GERD-HRQL score, Brazilian experts publish guideline on the management of obesity and prevention of CVD and obesity-associated complications, and mor